Objective: Body dysmorphic disorder (BDD) typically starts in adolescence, but evidence-based treatments are yet to be developed and formally evaluated in this age group. We designed an age-appropriate cognitive-behavioral therapy (CBT) protocol for adolescents with BDD and evaluated its acceptability and efficacy in a pilot randomized controlled trial.
INTRODUCTION
Body dysmorphic disorder (BDD) is a potentially severe psychiatric disorder characterized by excessive preoccupation with perceived defects or flaws in physical appearance that are not observable or appear only slight to others. This preoccupation leads to significant distress and impairment, time-consuming repetitive behaviors (e.g., grooming rituals, mirror checking, reassurance seeking), and marked avoidance (e.g., of social situations). 1 The disorder has an estimated prevalence of approximately 2% in community samples of adults [2] [3] [4] and is associated with high levels of occupational and social disability, including absenteeism, unemployment, marital dysfunction, and reduced quality of life.
5-7
BDD has received little empirical attention in adolescents, which is surprising given that an adolescent onset is reported in 70% of cases, with a mean age of onset around 16 years. 8 In young people, BDD results in major functional impairment, including social withdrawal, reduced academic performance, and dropping out of school. 9 Furthermore, the disorder is linked with strikingly high suicidality rates in adolescents, with a reported 21-44% of patients attempting suicide.
9-11
Unfortunately, the disorder often goes undetected in young people, as the symptoms of BDD may be mistakenly interpreted as normal developmental concerns (i.e., most teenagers worry about their appearance to some extent).
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There is growing evidence that cognitive-behavioral therapy (CBT) may be efficacious for adults with BDD. [12] [13] [14] [15] [16] [17] By contrast, the treatment literature for BDD in adolescents is very sparse; the only published evidence comes from single case studies [18] [19] [20] and a small case series of six adolescents. 21 The findings of these studies suggest that CBT is probably a feasible treatment option for adolescents with the disorder. Despite the lack of solid evidence, in the UK, clinical guidelines recommend CBT as a first-line treatment for children and adolescents with BDD. 22 There is an urgent need to develop, evaluate, and disseminate age-appropriate treatment protocols for young people with BDD.
In this study, we aimed to a) develop an age-appropriate CBT protocol for young people with BDD, involving their parents or carers when appropriate, and b) evaluate its acceptability and efficacy in a pilot randomized controlled trial (RCT). We predicted that the intervention would lead to a significantly greater reduction in BDD symptoms, compared to a control condition consisting of written psycho-education materials and weekly telephone monitoring, and that the therapeutic gains would be maintained two months after treatment. We also predicted that the intervention would be deemed acceptable and result in high levels of satisfaction in both the young people and their parents/carers.
METHOD
Design and participants
The study was a single blind RCT with two groups conducted at a single specialist center in England, United Kingdom, between February 2012 and August 2014. Patients were randomly allocated (1:1 ratio) to either 14 sessions of CBT delivered over a 4-month period or a control condition of equivalent duration consisting of written psycho-education materials and weekly telephone monitoring (henceforth "control"). Participants randomised to the control condition were offered CBT after a 2-month follow-up. There were no changes to the trial design after its commencement or any protocol violations.
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4 Participants recruited to the trial were those referred to the National and Specialist OCD [obsessive-compulsive disorder], BDD, and Related Disorders Clinic for Young People at the Maudsley Hospital. In addition to the usual referral channels, the trial was widely advertised across child and adolescent mental health services (CAMHS) using a range of methods, including specifically designed leaflets/posters, talks, and distributing brief screening questionnaires within community CAMHS. Additionally, advertisements were placed in social media sites, relevant charities' websites, and magazines for young people. A website was also created to advertise the study. Individuals showing interest in the treatment trial were requested to see their local CAMHS or general practitioner to seek a formal referral to the clinic.
Eligibility criteria for participants were as follows: a) age ranging from 12-18 years; b) a DSM-IV diagnosis of BDD; c) stable psychotropic medication for 12 weeks prior to randomization (if relevant); d) no plans to commence or increase the dose of psychotropic medication (if relevant); e) willingness to receive psychological treatment; f) willingness/ability to travel to the clinic for CBT;
and g) a score of 24 or higher on the Yale-Brown Obsessive-Compulsive Scale Modified for BDDAdolescent version (BDD-YBOCS-A).
23
Exclusion criteria were: a) current or past diagnosis of schizophrenia or bipolar affective disorder, current alcohol or substance dependence, severe disabling neurological disorder, global intellectual disability, autism spectrum disorder, or an emerging borderline personality disorder requiring treatment in its own right; b) suicidal intent that requires hospitalization; c) English too poor to engage in treatment; and d) characteristics interfering with completion of treatment (e.g., selective mutism).
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5 these patients. 21 For example, language was simplified, and age-appropriate worksheets and handouts were produced. In all cases, effort was made to include parents in psycho-education sessions at the start of treatment in order to ensure a shared understanding of BDD and learn how to best support the child in treatment. The extent to which parents/carers were included in subsequent sessions was decided in collaboration with the young person and guided by the individual case formulation, specifically considering the following factors: a) the level of parental involvement in BDD-related rituals, reassurance, and/or avoidance; b) the extent to which additional parental beliefs and/or behaviors were a barrier in treatment (e.g., high levels of parental criticism); and c) the extent to which parental involvement might inhibit disclosure or discussion of relevant experiences (e.g., shaming and humiliating experience within the family or within an intimate relationship). Control group: Participants randomized to the control condition were given written materials containing age-appropriate information about BDD, anxiety, and the link between thoughts, emotions, and behaviors (for details, see Supplement 1, available online). Importantly, these materials did not contain information regarding the treatment of BDD. Patients were able to email or phone the clinic with any questions they may have about the materials and for general support. Additionally, a research assistant phoned each patient once a week to monitor mood and suicidal ideation/intent or other risks.
During each call, the Patient Health Questionnaire (PHQ), 27, 28 which contains a question about suicide intent, was completed. All participants assigned to the control condition were offered CBT after the end of the two-month follow-up.
Assessment and outcomes
All patients and their families attended an initial assessment of approximately three hours with a multidisciplinary specialist team. Assessment included a mental state examination and an interview with the young person to obtain a detailed account of their BDD symptoms, and an interview with parents/carers to obtain a full developmental history and an independent account of current difficulties.
In addition, patients completed a number of standardized symptom measures. Demographic information (i.e., age, gender, ethnicity) was also collected.
Diagnosis of BDD was made according to DSM-IV criteria using the BDD section of the Structured Clinical Interview for DSM-IV (SCID-I). 29 Comorbid psychiatric diagnoses were established using the child version of the Anxiety Disorders Interview Schedule (ADIS-IV-C). Additionally, a treatment satisfaction questionnaire was developed to assess participant and parent/carer satisfaction with the intervention; this was administered at post-treatment to the CBT group only.
Power calculation
Based on data from two previous adult waitlist-controlled trials, 12, 13 calculations showed that, in order to detect a large effect size (i.e., d≥0.8) on the primary outcome measure at two-sided 5% alpha and 90% power, 11 participants would be required in each group. To allow for potential dropouts (up to 20% expected), cell sizes were set at 15 participants in each arm.
Randomization and concealment
Prior to the inclusion of patients, a randomization sequence was computer-generated using permuted block randomization (blocks of 4 patients, 1:1 ratio), chosen to avoid imbalanced group sizes.
Patients received their randomization number consecutively, based on the order of their inclusion in the trial. Sealed envelopes with information on treatment allocation were stored in a secure locker in case of emergency un-blinding. The allocation sequence was concealed from the research assessors.
The therapist was directly informed of the treatment allocation by the trial coordinator. Blinding was only broken after the last patient had completed the two-month follow-up appointment.
Implementation
The research assessor enrolled suitable participants in the trial and gained written informed consent from them (if they were 16 years of age or older) and their parents/carers for their participation in the study. Informed assent was gained from participants younger than 16 years of age after a detailed description of the study had been given. Participants were either randomized to receive 14 weekly sessions of BDD-specific CBT over four months, followed by a two-month follow-up, or to a control condition of equivalent duration (i.e., four months followed by another 2 months of follow-up).
Blinding
Trained independent assessors who were blind to condition completed all clinician-administered measures at all time-points. Treating therapists and participants/parents were instructed not to discuss the arm that they had been allocated to with the blinded assessors, and reminder cards were placed in the interview rooms. Where blindness was inadvertently broken (four patients at mid-treatment, three at post-treatment, and one at two-month follow-up), assessors were immediately changed.
Treatment Integrity
A random sample of n=49 (25%) audio-recorded therapy sessions were checked for integrity, using an adherence-to-protocol rating form developed for this study. The rate of adherence to the treatment manual was 86.7%, which is considered a high rate of treatment fidelity.
42
Statistical analyses
Across mid-treatment, post-treatment, and follow-up, there were four missing data points on the BDD-YBOCS-A and a similar number of missing data points on the secondary outcome measures.
Logistic regression analyses indicated that data were missing at random. Intent-to-treat (ITT) 
Ethics and trial monitoring
The study protocol was approved by the National Research Ethics Service Committee South East Coast -Kent (REC reference 11/LO/1605). External quality management of the study was provided by a steering committee including the project management team, carer and user representatives, expert advisors, and trial therapists.
RESULTS
Participant characteristics
Recruitment of participants took place between February 2012 and March 2014. Table 1 shows the demographic and clinical characteristics of the sample, which was predominantly female and Caucasian. One fifth were on medication at the time of the assessment and approximately 35% had had previous medication and CBT. Half were completely convinced that their perceived defect was real (delusional insight) and nearly half expressed desire to have a cosmetic procedure at baseline.
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10 Approximately 43% had current or a history of self-harm, and 17% a history of suicide attempts. More than half of the sample was either inconsistently or not attending school due to their BDD. Nearly 70% had at least one comorbid psychiatric diagnosis; the most frequent comorbidities were mood disorders (major depressive disorder or dysthymia; n=10, 33.3%), social phobia (n=10, 33.3%), specific phobias (n=8, 26.7%), and generalized anxiety disorder (n=4, 13.3%). More details can be found in Table S1 (available online).
-Insert Table 1 about hereParticipants reported the following main feature(s) of concern: nose (n=7; 23.3%), hair (n=6; 20%), skin (n=4; 13.3%), face in general (n=3; 10.0%), jaw line (n=2; 6.7%), body hair (n=2; 6.7%),
breasts (n=2; 6.7%), stomach (n=3; 10.0%), and other (including spots, mole, bags under the eyes, teeth, ears, body shape, thighs, hips, weight, feet, and genitalia; n=11; 36.7%).
Primary outcome
The participants' flow during the trial is depicted in Figure 1 . All patients in the CBT group completed treatment and provided data. In the control group, one participant dropped out immediately after randomization, and another was lost to follow-up.
-Insert Figure 1 about here - Table 2 shows the estimated means and standard errors (SE) from the mixed-effects model for each group and time-point. Raw means and SDs per group across measurement points for the BDD-YBOCS-A appear in Table S2, available to -2.58], SE=3.05; p=0.005).
-Insert Table 2 and Figure 2 about hereUsing one definition of treatment response (≥ 30% reduction in the BDD-YBOCS), 32 6
(40%) participants in the CBT group and one (6.7%) participant in the control condition were classified as responders at both post-treatment and follow-up (χ 2 =4.658, p=.031).
Between-groups effect sizes (for completers) were 1.13 (95%CI=0.31 to 1.96) at post-treatment and 0.85 (95%CI=0.02 to 1.69) at follow-up (Table S2 , available online).
Within-group effect sizes at post-treatment were 1.47 (0.46 to 2.47) and 0.32 (-0.29 to 0.94) for the CBT and control groups, respectively. Similarly, at two-month follow-up, within-group effect sizes were 1.38 (0.34 to 2.41) and 0.35 (-0.45 to 1.14), respectively ( Table S2 , available online). Table 2 shows the estimated means, standard error, and results of the mixed-effects model for all the secondary outcomes. Raw means and SD per group across measurement points for these variables are shown in Table S2 (available online). Overall, results from the mixed-effects models in the secondary measures were consistent with the magnitude of the between-and within-group effect sizes both at post-treatment and at two-month follow-up (see Table S2 , available online).
Secondary outcomes
The time×group interactions were significant for all the self-reported measures (all p's≤0.007) at post-treatment, favoring the CBT condition; this trend was maintained at two-month follow-up, although some of the interaction effects failed to reach statistical significance (see Table   2 ).
Eight (53%) CBT-treated patients were classed as improved or much improved on the clinician-rated CGI-I, compared to 0 in the control condition at post-treatment (see Figure S1 , available online). 
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Protocol deviations
The protocol stipulated duration of 14 CBT sessions over four months, but eight out of the 15 patients in the CBT group required more time to complete treatment (mean and median=18 weeks; range=13-28).
Three participants obtained or changed treatment off-protocol during their involvement in the trial. One participant (control group) discontinued medication (fluoxetine 10mg) without medical consultation approximately one month after being randomized. One patient (CBT group) started decreasing medication (fluoxetine 20mg) until discontinuation after the end of the CBT sessions and before they had reached the two-month follow-up. A third patient (CBT group) commenced fluoxetine (up to 40mg) during the active treatment phase (between sessions 1 and 7) and started additional psychological treatment in an inpatient psychiatric unit at post-treatment due to the persistence of severe BDD concerns and a suicide attempt (participant's BDD-YBOCS-A score at baseline=41; score at post-treatment=46).
Adverse events
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Two participants -one in each condition-attempted suicide during the trial. The attempts consisted of drug overdoses that required emergency attendance at hospital. Both patients stayed in the trial after the overdoses, though one patient in the CBT group (mentioned in the previous section) deviated from protocol and received additional pharmacological and psychological treatment in an inpatient unit. The participant in the control condition continued to be monitored by their local child and adolescent mental health service (this monitoring was not focused on the BDD symptoms and did not include active treatment for BDD).
DISCUSSION
To our knowledge, this is the first RCT to test the feasibility, acceptability, and efficacy of a developmentally tailored CBT protocol for young people with BDD. Both the patients and their families deemed the intervention highly acceptable and useful. CBT was superior to a control condition of equivalent duration (consisting of psycho-education materials and weekly risk monitoring) on both primary and secondary measures (e.g., insight, depression, general function) and the gains were generally maintained at two-month follow-up. Between-group effect sizes were large (1.13 at post-treatment and 0.85 at follow-up), as were the within-group effect sizes of CBT (1.47 at post-treatment and 1.38 at follow-up).
The results are broadly comparable to those in the adult CBT trials for BDD, 15-17 which reported response rates ranging from 48% to 61% and within-group effect sizes ranging from 0.83 to 1.30 after 12 weeks of treatment. Although these comparisons need to be made cautiously, because recruited samples and treatment protocols differ, our results suggest that CBT can also be developmentally tailored and successfully delivered to young people with the disorder, supporting the UK National Institute for Health and Care Excellence guidelines. 22 Despite this, the results could be It is important to note that ours was a severely ill sample (11 patients [37% of the sample]
had BDD-YBOCS scores over 40, and a further 6 patients had scores of 38 or 39, indicating very severe symptoms). Half of the sample was classed as having no insight (delusional) at baseline. A substantial proportion had a history of self-harm and suicidal attempts. Nearly 60% were off school or only attending sporadically due to their BDD symptoms. Nearly half desired cosmetic procedures.
Though the study protocol stipulated that the 14 CBT sessions should be delivered in four months, many patients missed sessions or had unproductive sessions, which were used to deal with low mood, family conflict, or risky situations like suicidal ideation or attempts. This resulted in a protocol adherence of around 87%, which is somewhat lower than that reported in the OCD literature. 45 Outside the tight control conditions of a clinical trial, we suspect that many of these patients would have dropped out from treatment. Our experience from this trial suggests that a considerable proportion of youths with BDD may require longer than 14 sessions, delivered weekly but with flexibility in terms of location and time of appointments, in order to achieve symptom relief. In support of this possibility, two recent adult trials 12, 14 showed that further improvements occurred when treatment was prolonged beyond the acute phase (12 sessions).
Compared to the adult BDD trials, our trial had a lower proportion of male patients (only 13%). A similar female predominance was observed in previous pediatric BDD studies. 9, 10 It is unclear whether BDD is less prevalent in adolescent boys or simply harder to detect. Further epidemiological research will be required to address this question and possibly identify barriers to seeking help amongst adolescent males. BDD is associated with considerable stigma and reluctance to disclose symptoms 46, 47 and perhaps this is particularly problematic in adolescent boys. medication during the trial. Exclusion of all data points after these medication changes did not alter the results. Second, blindness to condition was inadvertently broken in eight occasions during the duration of the trial. However, assessors were immediately changed when that occurred, thus minimizing the consequences of the un-blinding in posterior assessments. Third, though adequately powered to test the study hypotheses, this pilot study was too small to examine whether comorbidity (e.g., depression), low insight, or other variables are predictive of treatment outcome in youths with BDD. The identification of reliable predictors of outcome will be invaluable to inform future refinements of the protocol and to devise more personalized interventions. Fourth, the study was conducted in the context of a highly specialist clinic and the results may not generalize to other settings or less complex BDD populations. Finally, we used a control condition which included psychoeducation materials and careful monitoring of risk; however, despite weekly phone calls, patients in the control condition did not receive a comparable amount of therapist contact, potentially resulting in an inherent advantage for the CBT group beyond the active elements of the intervention (that is, non-specific effects associated with therapist contact). A larger RCT comparing an optimized version of this treatment with an active control condition, such as anxiety management, 13 is warranted. Similarly, a longer follow-up of these patients is also warranted to establish the durability of the treatment.
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To conclude, developmentally tailored CBT is a promising intervention for young people with The following modules were also included in the treatment manual and were used as appropriate depending on the case formulation, although they were not the main focus of treatment: a) mirror retraining; b) attention training; c) imagery rescripting for past aversive experiences (e.g., bullying, teasing); d) relaxation training; e) behavioral activation; f) mindfulness; g) distancing thoughts technique; and g) the "inner bully" technique. The emphasis of the treatment was exposure with response prevention (ERP) tasks. These additional modules were thus not the main focus of treatment, but rather used as appropriate, to either enhance ERP tasks or to enable the young person to fully engage in EPR tasks. This depended on the case formulation; for example, mirror retraining was used if the young person was particularly involved in rituals involving mirrors, and attention training was completed if young people were unable to effectively manipulate their internal focus of attention when doing exposure tasks. Among the group of 15 patients receiving CBT, 66.7% (n=10) completed the mirror retraining module, 53.3% (n=8) completed the attentional training module, 20.0% (n=3) the inner bully module, 6.7% (n=1) the imagery rescripting technique, and another 6.7% (n=1) completed the distancing thoughts module.
Control group: Written Psycho-Education Materials
Participants in the control group were given the following reading materials: 
